RxDoctor Payments Data

Brett Schaeffer, MD

Internal Medicine · Loma Linda, CANPI 1144753799

Payments from drug & device makers

$2,625in general payments, 2019–2025

Across 23 payments — averaging $114.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$1K
  • Boehringer Ingelheim$318
  • Regeneron Healthcare Solutions, Inc.$227
  • Shionogi Inc$217
  • Inari Medical, Inc.$150
  • AstraZeneca$150
  • plus $370 from 5 others

What the payments were for

  • Travel & lodging$1,09642%
  • Food & beverage$1,45155%
  • Education$783%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,625 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$51,562
Medicare patients
197
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$37,509
Spiriva HandihalerTiotropium Bromide21$12,448
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$9,689
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,887
Spiriva RespimatTiotropium Bromide13$6,523
Incruse ElliptaUmeclidinium Bromide15$5,435
SymbicortBudesonide/Formoterol Fumarate15$3,791
Albuterol Sulfate HfaAlbuterol Sulfate97$3,056
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,814
Wixela InhubFluticasone Propion/Salmeterol15$904
Roflumilast13$673
Bupropion Hcl SrBupropion Hcl17$402
Montelukast Sodium37$317
Prednisone14$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta$104$42,94460 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$318$16,21231 claims
AstraZenecaBreztri Aerosphere, Symbicort$150$12,67729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →